Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 9/20 | 0.62 |
| ▸ | TUBB | P07437 | 9/20 | 0.62 |
| ▸ | TUBA3C | P0DPH7 | 9/20 | 0.62 |
| ▸ | TUBA1B | P68363 | 9/20 | 0.62 |
| ▸ | TUBA4A | P68366 | 9/20 | 0.62 |
| ▸ | TUBB4B | P68371 | 9/20 | 0.62 |
| ▸ | TUBB3 | Q13509 | 9/20 | 0.62 |
| ▸ | TUBB2A | Q13885 | 9/20 | 0.62 |
| ▸ | TUBB8 | Q3ZCM7 | 9/20 | 0.62 |
| ▸ | TUBA3E | Q6PEY2 | 9/20 | 0.62 |
| ▸ | TUBA1A | Q71U36 | 9/20 | 0.62 |
| ▸ | TUBA1C | Q9BQE3 | 9/20 | 0.62 |
| ▸ | TUBB6 | Q9BUF5 | 9/20 | 0.62 |
| ▸ | TUBB2B | Q9BVA1 | 9/20 | 0.62 |
| ▸ | TUBB1 | Q9H4B7 | 9/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308227 | 0.85 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25855378 | 0.85 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL182048 | 0.83 | CA1 (0.57) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3260484 | 0.81 | TUBB4A (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL25304893 | 0.79 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10194542 | 0.79 | STIM1 (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2336592 | 0.78 | COMT (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6052518 | 0.77 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4645055 | 0.77 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL27911610 | 0.77 | COMT (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4460492-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | (INSERM) Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131677-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131677-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-13 | — | — | WO | disclosed |
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2657230-A1 | AMIDE DERIVATIVE AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-7671049-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | IL2, IL4, IL5 | TUBB4A 2415/4885TUBB 1990/4885TUBA3C 2964/4885 |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | GSK3B, GSK3A, PYGB | TUBB4A 1031/4885TUBB 729/4885TUBA3C 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.